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Several patients experience at least one drug-related problem and Pharmaceutical Care can change 
this reality. This work describes a model for structuring the pharmaceutical care service at a pharmacy 
training unit of the Brazilian Public Health System based on pharmacotherapy follow-up program of 
Parkinson’s disease patients’ results. From the follow-up results (phase 1), a Therapy Management 
Scheme was designed (phase 2). Of the 57 patients followed-up, 30 presented at least one drug-related 
problem and 42% were non-adherent to treatment, which supported the need of pharmacotherapy 
management. The Pharmacotherapy Management Scheme was proposed as a pharmaceutical care service 
model, which presents 6 steps: first, the pharmacist fills out the dispensing form and assesses patient´s 
pharmacotherapy, if there is a suspect problem, he is invited to the follow-up (steps 1 and 2) and they 
agree the first appointment. After that, pharmacist studies the patient’s case (study phase, steps 3 and 
4). At the second meeting, the pharmacist proposes the intervention needed, and at the third, assesses 
the intervention results and new problems (steps 5 and 6, respectively). The process ends when all 
therapeutics outcomes are reached. This practical model can significantly contributed to the development 
and organization of pharmaceutical care services.
Uniterms: Pharmaceutical care. Pharmacotherapy follow-up. Community pharmacy. Patients/safety. 
Parkinson’s disease/treatment.
Muitos pacientes vivenciam pelo menos um problema relacionado ao medicamento e à atenção 
farmacêutica pode mudar este fato. Este trabalho descreve um modelo para estruturar o serviço 
de atenção farmacêutica numa farmácia escola do Sistema Único de Saúde brasileiro baseado nos 
resultados de um programa de seguimento farmacoterapêutico de pacientes com Doença de Parkinson. 
A partir dos resultados do seguimento, um esquema de gerenciamento da farmacoterapia foi desenhado. 
Dos 57 pacientes acompanhados, 30 apresentaram um problema relacionado ao medicamento e 42% 
não aderiram ao tratamento, o que reforça a necessidade de gerenciar a farmacoterapia. O esquema 
proposto apresenta 6 passos: primeiro, o farmacêutico preenche o formulário de dispensação e avalia 
a farmacoterapia do paciente; caso haja suspeita de um problema, ele é convidado a participar do 
seguimento farmacoterapêutico (passos 1 e 2) e marcam a primeira consulta. Após esta, o farmacêutico 
estuda o caso (fase de estudo, passos 3 e 4). Na segunda consulta, o farmacêutico propõe as intervenções 
necessárias e, na terceira, avalia seus resultados e novos problemas (passos 5 e 6, respectivamente). O 
processo termina quando todos os objetivos terapêuticos são alcançados. Este modelo de prática pode 
contribuir significativamente para o desenvolvimento e organização de serviços de atenção farmacêutica.
Unitermos: Atenção farmacêutica. Seguimento farmacoterapêutico. Farmácia comunitária. Pacientes/
segurança. Doença de Parkinson/tratamento
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INTRODUCTION
Pharmaceutical Care (PC), described as “the 
responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improve patient’s quality 
of life” (Hepler, Strand, 1990), has been applied in many 
different clinical fields to manage and improve treatment 
outcomes using a follow-up method (Chisholm-Burns 
et al., 2008; de Lyra et al., 2007; Lee, Grace, Taylor, 
2006; Koshman et al., 2008). The Brazilian Consensus 
in Pharmaceutical Care, which was created in 2002, 
had considered Pharmacotherapy Follow-up (PF) as 
one of the Pharmaceutical Care components, defined 
as a professional practice in which the pharmacist is 
responsible for patient medication needs. This is carried 
out by means of detection, prevention and solution of a 
Drug Related Problem (DRP) and implies a continuous, 
systemized and documented commitment on behalf of 
the pharmacist, in collaboration with the patient and other 
healthcare professionals, with the objective of reaching 
concrete results that improve the patient’s quality of 
life (Pan American Health Organization, 2002; Grupo 
de Consenso, 2001). Furthermore, Brazilian Resolution 
number 44 of the National Agency of Sanitary Vigilance 
(ANVISA), an agency which monitors and advocates 
for good pharmaceutical practice, regulated PC as one 
of the pharmaceutical services that can be carried out in 
community pharmacies (Brasil, 2009a).
Parkinson’s disease (PD) is a chronic neuro-
degenerative disease that usually causes severe disability 
after 10 to 15 years. Its social and financial impact is 
high, particularly among the elderly, with a prevalence 
of 1% of the population older than 60 (Martin, Dawson, 
Dawson, 2011). It is estimated that the annual global 
cost of antiparkinsonian drugs is around 11 billion US 
dollars, and it is about 3 to 4 times more expensive for 
patients in advanced stages of the disease (Bialecka et 
al., 2008). Furthermore, these patients are polymedicated 
and normally present multi-morbidity, increasing the risk 
of experiencing problems related to medicines (Schröder 
et al., 2011).
These patients normally have a complex pharmaco-
therapy, as they need to take a number of different 
medicines several times per day, thus, non-adherence 
and drug-drug interactions are common DRP (Obreli-
Neto et al., 2012). Furthermore, as the disease worsens 
the number of doses taken per day increases in order 
to maintain control over the physical symptoms. 
Moreover, the probability of the occurrence of either an 
Adverse Drug Reaction (ADR) or treatment resistance 
increases. On the other hand, non-motor symptoms (such 
as depression, hallucinations, etc) have an important 
impact on quality of life and on treatment compliance 
and effectiveness (Chaudhuri, Schapira, 2009). All 
these factors indicate the need for follow-up for these 
patients.
Pharmaceutical assistance policy and clinical 
and patient-centered care are part of the undergraduate 
curriculum of the Faculty of Pharmacy of the Federal 
University of Santa Catarina and, in order to put this 
knowledge into practice, the Pharmacy Training Unit has 
developed a partnership with the local city government. 
The Training Unit (called Pharmacy School UFSC/PMF) 
is part of the Brazilian Public Health System (SUS) and 
medicines - selected from a drugs list based on guidelines 
and therapeutics protocols for chronic diseases so as to 
guarantee the most complete treatment coverage through 
the rational use of medicines known as “specialized 
component” of the National Pharmaceutical Assistance 
Policy - are dispensed monthly without direct cost to the 
patients (Brasil, 2007, 2009b). A median of 7000 patients 
are assisted per month and, among these, 170 are suffering 
from Parkinson’s disease.
Thus, our objective was to propose a practical 
model for structuring the pharmaceutical care service at a 
pharmacy training unit based on the results derived from 
a previous experience of a pharmacotherapy follow-up 
program of Parkinson’s disease patients.
PATIENTS AND METHODS
The present study was performed in two phases 
described as follow:
Phase 1
Study design and clinical setting
This study is a description of a pharmacotherapy 
follow-up of Parkinson’s disease patients carried out at 
the School of Pharmacy UFSC/PMF, which is a pharmacy 
training unit of the university. 
Previous Pharmacotherapy Follow-up
Patients were enrolled in the follow-up between 
May and August of 2011 when they came to receive their 
antiparkinsonian treatment and included after accepting 
and signing the informed consent form. They had an 
appointment once a month with the pharmacist for a period 
of 4 months or until the DRPs were solved, however only 
the data from the first interview was used in this study. 
Follow-up data were statistically analyzed by ANOVA 
using SPSS version 15. The study was approved by the 
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Ethical Committee in Human Research of the Federal 
University of Santa Catarina.
Follow-up method
The Dáder pharmacotherapy follow-up method 
was adapted to this study (GIAF-UGR, 2005a). This 
involves a structured clinical questionnaire based on 
information retrieval about patient’s health problems 
and pharmacotherapy. The questionnaire is applied at the 
first appointment and allows the clinical pharmacist to 
evaluate the patient’s clinical history and identify DRPs, 
formulate an individualized and adequate action plan for 
the patient and put in place pharmacotherapy interventions 
that may be required. The method design is continuous and 
documented, thus, the pharmacist performs successive 
interviews during a period of time with each patient and 
archives all clinical, pharmacological and demographic 
information. At the second meeting, the pharmacist can 
review the treatment and apply the intervention and at 
the third meeting he/she can evaluate the intervention 
results and the necessity of continuing the follow-up. 
All information was recorded in a specific database for 
this study. DRPs were classified according to the Third 
Consensus of Granada in DRP (Consensus Committee, 
2007).
Adherence measurement
To evaluate treatment adherence, the Moriski-
Green-Levine validated adherence questionnaire was 
applied (Morisky, Green, Levine, 1986).
PD severity 
Hoehn & Yahr stage scale (H&Y) was used to assess 
disease severity (Hoehn, Yahr, 1967).
Quality of life measurement
Quality of life was evaluated using the Parkinson’s 
Disease Questionnaire (PDQ39) (Souza, 2007). As there 
is no validated range score to interpret the PDQ39 (0 is 
considered the best and 100 the worst) (Peto, Jenkinson, 
Fitzpatrick, 2001) the global score in this study was 
divided into two categories: scores ≤50 and scores >50, 
the lower the value under 50, the better the quality of life.
Phase 2
Pharmaceutical care service model
As a proposal to put in practice the pharmaceutical 
care service, a pharmacotherapy management scheme to 
manage patient´s pharmacotherapy was designed based on 
previous pharmacotherapy follow-up results.
RESULTS
Phase 1
Previous pharmacotherapy follow-up of PD patients
Fifty seven patients were followed-up, 54.4% men, 
mean age of 71.4±9 years old, 61.4% did not have a 
caregiver and 61.4% were married. Regarding schooling, 
67% (38) had studied at least eight years (including 
graduates) and 12.3% (7) were illiterate. The mean 
diagnostic age was 6.4±4 years and the majority of them 
(53%) presented stage 1 on the Hoehn & Yahr stage scale, 
followed by 32% on stage 2.
The first appointment with the pharmacist lasted 
about 33±10 minutes. The main issues reported by patients 
were: lack of information about disease progression, 
prognosis and antiparkinsonian medication, drug 
interaction, nauseas, the occurrence of nightmares and 
hallucinations, difficulties in complying with treatment 
regimen and depression.
The results from the pharmacotherapeutic history 
recorded are described as follows:
Medication and Drug Related Problems
The average dosage of antiparkinsonian and 
concomitant drugs taken per day are listed in Table I. In 
addition to Parkinson’s disease the majority of patients 
presented other chronic health problems treated with 
medication, such as hypertension (38.6%) and hypertension 
plus diabetes mellitus (15.8%). Regarding DRPs, 30 
patients (52.6%) presented at least one and amongst these, 
26 (45.6%) had ADRs due to levodopa combinations 
(levodopa/carbidopa or levodopa/benserazide). The most 
cited DRPs were ADRs, hallucinations and constipation.
Adherence
From these patients, 42% were non-adherent to their 
treatment. The treatment regimen and ADRs were the main 
causes for this. PDQ 39 scores, duration of disease, age, 
PD severity and patient schooling did not present statistical 
association with adherence. Table I contains these results 
in detail.
Quality of life
The quality of life of Parkinson’s patients is strongly 
affected by motor and non-motor signs and symptoms. 
These patients presented a global score on the PDQ39 of 
39.2±19.3, which is considered good. Older patients (15, 
median age of 76.7 years) presented a worse score (>50%) 
than the others (p=0.005). Regarding the subscales, bodily 
discomfort presented the worst ranking with a mean of 
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51.6±25.3, followed by mobility problems (48.4±3) and 
daily activities (47.5±28.5). Patients reported social stigma 
and social support as the factors that least affected them 
(19.5±25 and 19.2±23, respectively). Total PDQ39 score 
in communication, bodily discomfort, daily activities 
and mobility were affected by PD severity (p=0.02, 
0.021, 0.03, 0.001 and 0.005, respectively), as stage 1 
patients presented a better score compared with stage 2 
or above patients. Apart from these results, the total score 
and subscales were related to the duration of the disease 
(p<0.001 for all).
PHASE 2: PHARMACEUTICAL CARE SERVICE 
PROPOSAL
As part of the improvement of the quality of 
patient-centered care services, during the follow-up, a 
scheme of Pharmacotherapy management was developed 
to support the implementation of the Pharmaceutical 
Care service at the pharmacy. This scheme was designed 
taking into account both the service and patients’ needs 
and specificities. This service began with treatment 
dispensation (which included the pharmacist actions 
regarding the analysis of the prescription, patient 
counseling and medicine provision), evaluation of patients’ 
follow-up needs (by filling out the dispensation form every 
three months, as not all patients presented a DRP) and 
the follow-up itself (individualized and specialized care). 
This whole process was called the Pharmacotherapy 
management scheme and comprises 6 steps: first, when 
patients come to the pharmacy to collect their treatment, 
the pharmacist asks some questions evaluating their 
pharmacotherapy and fills out the dispensing form, and 
if he/she notices that patients have a need, he/she invites 
them to participate in the pharmacotherapy follow-up 
(steps 1 and 2); then, they agree on the first appointment 
(first interview). After the first meeting, the pharmacist 
studies the patient’s case and identifies DRPs (the 
study phase, steps 3 and 4). At the second meeting, the 
pharmacist proposes an intervention to the patient or to 
the physician, and at the third the pharmacist evaluates 
if the intervention was effective and if there are any new 
TABLE I - Patients baseline study data (n=57)
Age (years, mean±SD) 71.4±9
Gender (male/female, %) 54.4/45.6
Schooling (%)
Illiterate – 12.3
Just read and write – 3.5
Incomplete elementary school – 17.5
Complete elementary school – 14
Incomplete high school – 1.8
Complete high school – 28.1
Graduate – 22.8
Retired (%) 80
Duration of disease (years, mean±SD) 6.44±4
Caregiver (Yes, %) 38.6
Parkinson Disease medication (mean±SD) 2.3±0.7
Concomitant medication (mean±SD) 4.7±3
H&Y stage (%)
1 – 52.6
2 – 31.6
3 – 8.8
4 – 5.3
5 – 1.8
PDQ39 total scale (%) ≤50 – 68.4
>50 – 31.6
Moriski-Green-Levine (%) NA – 42
DRP (%)
1 – 52.6
2 – 8.8 
None – 38.6
ADR (%) Yes – 45.6
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FIGURE 1 - Pharmacotherapy management scheme.
problems (steps 5 and 6, respectively). If there are any new 
problems, the pharmacist arranges a new appointment with 
the patient and the process starts again until all DRPs are 
solved and therapeutic outcomes reached (see Figure 1).
DISCUSSION
Because Parkinson’s disease is a neurodegenerative 
disease it includes, besides the classical symptoms, 
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psychosocial and non-motor problems which can strongly 
affect these patients’ quality of life (Tedrus, Fonseca, 
Kange, 2010). Thus, these patients require more attention 
from health professionals to ensure the correct and safe use 
and the adherence of medicines to attain desired clinical 
outcomes. In this study, PD patients’ data were used to 
demonstrate the importance of specialized care (follow-
up) for any person with a chronic disease and to support the 
development of pharmaceutical care service by designing 
a pharmacotherapy management scheme.
It has already been shown that pharmacotherapy 
follow-up programs can improve adherence, decrease 
adverse effects and generate better clinical outcomes as 
well as promote the rational use of medicines (de Lyra et 
al., 2007; Lee, Grace, Taylor, 2006; Viktil, Blix, 2008). 
However, in Brazil, this service is still in development (de 
Castro, Correr, 2007; Pan American Health Organization, 
2002; Pereira, Freitas, 2008) and pharmacists who work 
in schools of pharmacy have the responsibility to share 
their knowledge and contribute to the development of this 
area, the results of which should improve patient’s health 
and the public health system itself, in relation to the cost-
effectiveness of treatments provided. Furthermore, the 
development of a pharmacotherapy management scheme 
is necessary to provide appropriate training and knowledge 
to pharmacists, and to encourage the development of a 
PF guide, as is the case for other chronic health problems 
(Sabater-Hernández, 2011; GIAF-UGR, 2005b; GIAF-
UGR, 2009).
The results of Phase 1 revealed a PD population with 
similar demographic characteristics to the epidemiology 
data previously reported (Davis, Edin, Allen, 2010) 
and describe the need for individualized care due to 
polymedication and DRPs presented. Complex treatment 
posology and ADRs are likely reasons for the large number 
of DRPs, as well as a delayed perception of improvement 
in clinical symptoms.
Problems related to non-adherence appear to be the 
most common DRP among patients with chronic diseases 
and are related to the increasing costs of healthcare 
services (Grosset D, European PD Therapy Compliance 
Study Group, 2010; WHO, 2003; Stuart et al., 2011). The 
present results agree with these data, showing that 42% of 
the patients studied did not adhere to their pharmacological 
treatment. Non-adherence could be responsible for the 
ineffectiveness of medication leading to misconceptions on 
the part of physicians when prescribing a drug regimen and 
dose titration and, sometimes, leading to the prescription 
of a new medication that increases costs. Furthermore, the 
majority of these patients are polymedicated, have suffered 
an ADR, a fact that could accentuate non-adherence. It is 
important to note that differently to other studies, non-
adherence in this group was not associated to PDQ 39 
scores, duration of disease, age, PD severity and schooling 
(Grosset, Reid, Grosset, 2005).
Non-adherence can arise from prescriber-patient 
communication, thus a good communication between 
them is important to attain clinical objectives and avoid 
misunderstandings. However, sometimes this is not 
the case. To manage patients’ treatments, physicians 
assume that they are adherent and make decisions based 
on this; on the other hand, sometimes patients do not 
understand the information and the reason for taking so 
many medicines, and the consultation time is insufficient 
for effective communication (Grosset D, European PD 
Therapy Compliance Study Group, 2010). Furthermore, 
patients’ experience with medication and their routine 
have to be taken into account in decision-making and in 
order to prevent new DRPs, that is, making patients active 
in their treatment (Shoemaker, 2011; Hibbard, 2004). As 
an example of it, this study revealed that some patients 
reported that symptoms alerted them to the need to take 
the next dose (referring to diskinesia, shaking, etc) and 
as a result, they did not forget to take their medication. 
However, patient did not tell their specialist about it. 
Thus, sometimes patients and physicians need a support 
to achieve the desired clinical outcome, and here comes 
the clinical pharmacist´s role, reviewing if patients have 
sufficient understanding, knowledge and skills to follow 
their pharmacotherapeutic regimens and, monitoring 
plans and providing education in partnership with other 
healthcare professionals (American Society of Health-
System Pharmacists, 1997; Wilson et al, 2011).
Regarding quality of life, is already known that it is 
an important factor for PD patients and their families. As 
in other studies, these patients had negative perceptions 
in relation to bodily discomfort, mobility and carrying out 
daily activities (Tedrus, Fonseca, Kange, 2010; Carod-
Artal, Vargas, Martinez-Martin, 2007), as they reported 
difficulties in performing everyday activities, such as 
brushing teeth. As the disease progresses, it is expected 
that its severity and duration further affect quality of life 
(Welsh, 2008), as reported by these patients and it can 
influence in desired treatment adherence and clinical 
outcomes.
All above justify the implementation of the practice 
of Pharmaceutical care at the Pharmacy School and 
supports the pharmacotherapy management scheme 
proposed in phase 2 of this study. However, to make this 
a well-based service, clinical pharmacist must have in 
mind that PC is focused on a patient-centered approach 
and the intervention plan is based on shared decision-
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making between patients and pharmacists, as well as 
patient education. If patients do not feel comfortable 
and do not trust their pharmacist, the process fails. For 
this reason, patient-pharmacist communication has to be 
based on trust and empathy, allowing patients to be active 
and make decisions in a collaborative way in relation to 
their treatment, in order to meet their needs and wishes 
(McKinstry et al. 2006; Légaré et al., 2010).
Furthermore, the consolidation of PC at SUS 
through PF turns the pharmacist into a healthcare provider, 
establishing a link between the patients and pharmacists, 
stimulating user responsibility for their health and, finally, 
enabling a multidisciplinary care team to improve patients’ 
quality of life (Brasil, 1998). According to the present 
results, pharmacists would have a better view of these 
patients’ needs and wishes, thus their work would be more 
focused on these aspects. The pharmaceutical management 
scheme proposed in this study will enable patients to be 
screened when they go to the pharmacy to collect their 
medication, identifying DRPs and the need for follow-
up in a practical manner without interrupt the routine 
(Pawloski, Cusick, Amborn, 2012). Furthermore, by 
evaluating whether the prescription is appropriate and by 
assessing effectiveness, safety and adherence, medication 
use can be optimized and unnecessary healthcare spending 
can be avoided.
CONCLUSION
This  mode l  p roposed  fo r  s t ruc tu r ing  the 
pharmaceutical care service in the Pharmacy school 
showed to be a practical and effective pharmacotherapy 
management strategy, once all patients will benefit 
significantly through an improvement in their clinical 
outcomes by increasing patient safety and treatment 
effectiveness.
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